Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

A randomized, open-label pharmacokinetic trial of tacrolimus extended-release dosing in obese de novo kidney transplant recipients.

Jasiak-Panek NM, Wenzler E, Patel S, Thielke JJ, Progar K, Patel S, Brandt S, Huang YJ, Benedetti E, West-Thielke PM.

Clin Transplant. 2019 Jun 17:e13640. doi: 10.1111/ctr.13640. [Epub ahead of print]

PMID:
31206808
2.

Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model.

Meyer KA, Deraedt MF, Harrington AT, Danziger LH, Wenzler E.

Int J Antimicrob Agents. 2019 Apr 26. pii: S0924-8579(19)30104-9. doi: 10.1016/j.ijantimicag.2019.04.010. [Epub ahead of print]

PMID:
31034937
3.

A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia.

Biagi M, Butler D, Tan X, Qasmieh S, Wenzler E.

Antibiotics (Basel). 2019 Mar 16;8(1). pii: E27. doi: 10.3390/antibiotics8010027. Review.

4.

In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.

Wu T, Meyer K, Harrington AT, Danziger LH, Wenzler E.

J Antimicrob Chemother. 2019 Feb 8. doi: 10.1093/jac/dkz010. [Epub ahead of print]

PMID:
30753495
5.

Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms.

Wenzler E, Lee M, Wu TJ, Meyer KA, Shields RK, Nguyen MH, Clancy CJ, Humphries RM, Harrington AT.

J Antimicrob Chemother. 2019 Mar 1;74(3):633-638. doi: 10.1093/jac/dky483.

PMID:
30534964
6.

Implementation and optimization of molecular rapid diagnostic tests for bloodstream infections.

Wenzler E, Timbrook TT, Wong JR, Hurst JM, MacVane SH.

Am J Health Syst Pharm. 2018 Aug 15;75(16):1191-1202. doi: 10.2146/ajhp170604. Epub 2018 Jul 3. Review.

PMID:
29970407
7.

Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants.

Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA; Antibacterial Resistance Leadership Group.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00464-18. doi: 10.1128/AAC.00464-18. Print 2018 Aug.

8.

Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae.

Bunnell KL, Wenzler E, Harrington AT, Danziger LH.

Diagn Microbiol Infect Dis. 2018 Apr;90(4):335-336. doi: 10.1016/j.diagmicrobio.2017.12.007. Epub 2017 Dec 16.

PMID:
29395714
9.

Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.

Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02475-17. doi: 10.1128/AAC.02475-17. Print 2018 Apr.

10.

Clinical use of the polymyxins: the tale of the fox and the cat.

Wenzler E, Bunnell KL, Danziger LH.

Int J Antimicrob Agents. 2018 May;51(5):700-706. doi: 10.1016/j.ijantimicag.2017.12.023. Epub 2018 Jan 3.

PMID:
29305954
11.

Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile.

Guinta MM, Bunnell K, Harrington A, Bleasdale S, Danziger L, Wenzler E.

Ann Clin Microbiol Antimicrob. 2017 Dec 4;16(1):77. doi: 10.1186/s12941-017-0252-7.

12.

Reply to Dilworth et al.

Wenzler E, Wang F, Goff DA, Prier B, Mellett J, Mangino JE, Bauer KA.

Clin Infect Dis. 2017 Nov 13;65(11):1957-1958. doi: 10.1093/cid/cix677. No abstract available.

PMID:
29020165
13.

Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection.

Bauer KA, Johnston JEW, Wenzler E, Goff DA, Cook CH, Balada-Llasat JM, Pancholi P, Mangino JE.

Anaerobe. 2017 Dec;48:1-6. doi: 10.1016/j.anaerobe.2017.06.009. Epub 2017 Jun 21.

PMID:
28645479
14.

Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.

Wenzler E, Ellis-Grosse EJ, Rodvold KA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00775-17. doi: 10.1128/AAC.00775-17. Print 2017 Sep.

15.

Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.

Wenzler E, Deraedt MF, Harrington AT, Danizger LH.

Diagn Microbiol Infect Dis. 2017 Aug;88(4):352-354. doi: 10.1016/j.diagmicrobio.2017.05.009. Epub 2017 May 18.

PMID:
28602518
16.

Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.

Meyer K, Santarossa M, Danziger LH, Wenzler E.

Hosp Pharm. 2017 Mar;52(3):221-228. doi: 10.1310/hpj5203-221.

17.

Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.

Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00464-17. doi: 10.1128/AAC.00464-17. Print 2017 Jul.

18.

An Automated, Pharmacist-Driven Initiative Improves Quality of Care for Staphylococcus aureus Bacteremia.

Wenzler E, Wang F, Goff DA, Prier B, Mellett J, Mangino JE, Bauer KA.

Clin Infect Dis. 2017 Jul 15;65(2):194-200. doi: 10.1093/cid/cix315.

PMID:
28379326
19.

Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.

Wenzler E, Goff DA, Humphries R, Goldstein EJC.

Infect Dis Ther. 2017 Jun;6(2):149-172. doi: 10.1007/s40121-017-0149-y. Epub 2017 Mar 4. Review.

20.

Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Wenzler E, Fraidenburg DR, Scardina T, Danziger LH.

Clin Microbiol Rev. 2016 Jul;29(3):581-632. doi: 10.1128/CMR.00101-15. Review.

21.

Controversies in Antimicrobial Stewardship: Focus on New Rapid Diagnostic Technologies and Antimicrobials.

Wenzler E, Wong JR, Goff DA, Jankowski CA, Bauer KA.

Antibiotics (Basel). 2016 Jan 14;5(1). pii: E6. doi: 10.3390/antibiotics5010006.

22.

Urinary Tract Infections: Resistance Is Futile.

Wenzler E, Danziger LH.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2596-7. doi: 10.1128/AAC.00006-16. Print 2016 Apr. No abstract available.

23.

Impact of rapid identification of Acinetobacter Baumannii via matrix-assisted laser desorption ionization time-of-flight mass spectrometry combined with antimicrobial stewardship in patients with pneumonia and/or bacteremia.

Wenzler E, Goff DA, Mangino JE, Reed EE, Wehr A, Bauer KA.

Diagn Microbiol Infect Dis. 2016 Jan;84(1):63-68. doi: 10.1016/j.diagmicrobio.2015.09.018. Epub 2015 Sep 30.

PMID:
26603136
24.

Clinical and microbiological outcomes in patients with Streptococcus anginosus group bacteraemia identified through use of a rapid microarray assay.

Wenzler E, Chandrasekaran V, Salvador P, Anwar M, Pancholi P, McGwire BS.

J Med Microbiol. 2015 Nov;64(11):1369-74. doi: 10.1099/jmm.0.000176. Epub 2015 Sep 25.

PMID:
26408191
25.

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.

Wenzler E, Gotfried MH, Loutit JS, Durso S, Griffith DC, Dudley MN, Rodvold KA.

Antimicrob Agents Chemother. 2015 Dec;59(12):7232-9. doi: 10.1128/AAC.01713-15. Epub 2015 Sep 8.

26.

Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.

Wenzler E, Rodvold KA.

Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S38-47. doi: 10.1093/cid/civ522. Review.

PMID:
26316557
27.

Hepatitis C Management and the Infectious Diseases Pharmacist.

Wenzler E, Dickson W, Vibhakar S, Adeyemi OM, Danziger LH.

Clin Infect Dis. 2015 Oct 1;61(7):1201-2. doi: 10.1093/cid/civ545. Epub 2015 Jul 1. No abstract available.

PMID:
26136390
28.

Severe Sepsis Secondary to Persistent Lysinibacillus sphaericus, Lysinibacillus fusiformis and Paenibacillus amylolyticus Bacteremia.

Wenzler E, Kamboj K, Balada-Llasat JM.

Int J Infect Dis. 2015 Jun;35:93-5. doi: 10.1016/j.ijid.2015.04.016. Epub 2015 Apr 27.

29.

Editorial commentary: improving prescribers to advance antimicrobial stewardship.

Wenzler E, Rodvold KA, Danziger LH.

Clin Infect Dis. 2015 Apr 15;60(8):1259-61. doi: 10.1093/cid/civ021. Epub 2015 Jan 16. No abstract available.

PMID:
25595751
30.

The Antimicrobial Stewardship Approach to Combating Clostridium Difficile.

Wenzler E, Mulugeta SG, Danziger LH.

Antibiotics (Basel). 2015 Jun 17;4(2):198-215. doi: 10.3390/antibiotics4020198. Review.

31.

Hyperhomocysteinemia in retinal artery and retinal vein occlusion.

Wenzler EM, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF.

Am J Ophthalmol. 1993 Feb 15;115(2):162-7.

PMID:
8430725
32.

[Report from Man, Ivory Coast].

Wenzler E.

Dtsch Schwesternztg. 1968 Sep;21(9):447-9. German. No abstract available.

PMID:
4300249

Supplemental Content

Loading ...
Support Center